Latest Commercialization News

Page 18 of 446
Noxopharm Limited has secured a major scientific milestone with the publication of its Sofra™ platform research in Nature Immunology, highlighting a novel anti-inflammatory mechanism with broad therapeutic potential.
Ada Torres
Ada Torres
11 Feb 2026
Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.
Ada Torres
Ada Torres
11 Feb 2026
James Hardie Industries reported a robust 30% jump in Q3 FY26 net sales, driven by the AZEK acquisition and growth in key regions, while operating income declined amid integration costs and market softness.
Victor Sage
Victor Sage
11 Feb 2026
TruScreen has been confirmed as a superior primary cervical cancer screening device in the world’s largest opto-electronic study, outperforming traditional cytology and matching HPV testing accuracy.
Ada Torres
Ada Torres
11 Feb 2026
CSL Limited has released its half-year results showing a slight revenue decline amid ongoing transformation efforts, while maintaining its full-year guidance and expanding its share buyback program.
Ada Torres
Ada Torres
11 Feb 2026
CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.
Ada Torres
Ada Torres
11 Feb 2026
CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.
Ada Torres
Ada Torres
11 Feb 2026
Commonwealth Bank of Australia’s latest Basel III Pillar 3 disclosures reveal steady capital adequacy ratios and proactive adaptation to evolving regulatory standards as of December 2025.
Claire Turing
Claire Turing
11 Feb 2026
Ark Mines Limited has signed a pivotal Memorandum of Understanding to trial processing of monazite ore from its Sandy Mitchell Rare Earths Project, aiming to recover critical minerals including Thorium, Neodymium, and Praseodymium.
Maxwell Dee
Maxwell Dee
10 Feb 2026
Island Pharmaceuticals has confirmed the material significance of recent FDA feedback on its Galidesivir development pathway and addressed ASX queries on disclosure timing and capital raising activities.
Ada Torres
Ada Torres
10 Feb 2026
Electro Optic Systems (EOS) has firmly rejected allegations from a recent Grizzly Research report, highlighting its strengthened financial position, significant contract wins, and strategic acquisition to bolster its defence technology portfolio.
Victor Sage
Victor Sage
10 Feb 2026
Revolution Private Credit Income Trust has launched a A$60 million institutional placement at A$2.00 per unit, aiming to bolster its investment in senior secured loans across Australia and New Zealand. The trust targets a net yield to maturity of 7.83%, emphasizing disciplined risk management and transparency.
Victor Sage
Victor Sage
10 Feb 2026